Novartis earns adcomm's vote of support in comeback FDA review for Entresto in sought-after heart failure patients
Novartis’ Entresto once seemed left for dead in its pursuit of a set of holy-grail heart failure patients, but the FDA turned the tide after …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
